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Abstract 
Introduction 
Trials of surgical procedures in the treatment of malignant disease face a unique set 
of challenges. This review aimed to describe recommendations for the design, 
delivery and reporting of randomised trials in surgical oncology. 
Methods 
A literature search was performed without date limits to identify articles related to trial 
methodology research in surgery, and surgical oncology. A narrative review was 
framed around two, open National Institute of Health Research portfolio trials in 
colon and rectal cancer: the STAR-TREC trial (ISRCTN14240288) and ROCCS trial 
(ISRCTN46330337). 
Results 
Twelve specific challenges were highlighted: Standardisation of technique; Pilot and 
feasibility studies; Balancing treatments; The recruitment pathway; Outcome 
measures; Patient and public representation; Trainee-led networks; Randomisation; 
Novel techniques and training; Learning curves; Blinding; Follow-up. Evidence based 
recommendations were made for future design and conduct of surgical oncology 
trials 
Conclusion 
Better understanding of the challenges facing trials in the surgical treatment of 
cancer will accelerate high quality evaluation, and rapid adoption of innovation for 
the benefit of patient care. 
Highlights 
• Trials in surgical oncology face a unique set of challenges in their design, 
conduct and delivery. 
• Methodological research and experiential learning have increased the volume 
and quality of pragmatic surgical trials over the past two decades. 
• This narrative review frames recommendations for trials in surgical oncology 
around two NIHR portfolio trials (STAR-TREC and ROCSS) 
• Better understanding these challenges will accelerate evaluation of complex 
surgical interventions. 
 
 
  
Introduction 
Trials in surgical oncology are characterised by the evaluation of surgical, or 
interventional procedures in at least one treatment group. They include patients 
undergoing curative or palliative treatment for malignant disease. The complexity of 
trials involving surgical interventions has historically led to a paucity of randomised 
evidence in the surgical management of cancer (1, 2). Unique challenges arise in 
each phase of the research pathway; from protocol design, to the recruitment 
consultation, randomisation, blinding, standardisation of the experimental 
intervention, outcome selection and assessment, ethics and reporting. This has led 
to failure to recruit patients into surgical trials (3), introduction of bias (4), 
discontinuation of trials (5), and misreporting (6-8). 
Twenty years ago, a systematic review demonstrated that the proportion of 
treatments supported by randomised evidence in surgery was almost half that of 
general medicine (9). Efforts to better understand this complexity have improved the 
quality and volume of surgical trials since this time. Specific recommendations have 
been made to improve the way surgical trials are designed, delivered and reported 
(10), but a number of practical difficulties persist. This article describes contemporary 
recommendations in the design, conduct and reporting of randomised trials in 
surgical oncology.  
Methods 
A narrative review was synthesised, describing challenges and recommendations for 
design, delivery and reporting of randomised trials in surgical oncology. A literature 
search was performed using PubMed and OVID via Medline, with the MeSH terms 
“surgical” OR “surgery” OR “surg*”; AND “trial” OR “randomised”; AND 
“methodology” OR “design” OR “conduct” OR “recruitment” OR “reporting” (last 
accessed: 1st June 2017). No date restrictions were imposed. Non-English language 
papers were excluded. The ‘related articles’ function, references and citation lists 
were used to identify additional relevant content. 
The review framed around two examples of surgical trials in colon and rectal cancer 
from the National Institute of Health Research portfolio (11):  
1. STAR-TREC: Can we save the rectum by watchful waiting or transanal 
surgery following (chemo)radiotherapy versus total mesorectal excision for 
early rectal cancer? (ISRCTN14240288) 
2. ROCSS: Reinforcement of Closure of Stoma Site. A randomised controlled 
trial of reinforcement of closure of stoma site using a biological mesh 
(ISRCTN46330337).  
Themes were illustrated with practical examples from the two trials. 
  
Trial example 1: STAR-TREC 
Can we save the rectum by watchful waiting or transanal surgery following 
(chemo)radiotherapy versus total mesorectal excision for early rectal cancer? 
(ISRCTN14240288) 
Trial summary 
STAR-TREC (12) is a multicentre international randomised, 3 arm-parallel, phase II 
feasibility study in patients with biopsy proven adenocarcinoma of the rectum (IDEAL 
phase 2B(13)). Patients with rectal cancer, staged by CT and MRI as ≤ cT3b (up to 
5mm of extramural spread) N0M0 can be included. STAR-TREC will assess the 
ability to recruit to a large, IDEAL phase 3, multi-centre randomised trial comparing 
radical surgery versus organ saving treatment (Figure 1). Participants are 
randomised in a 1:1:1 ratio to receive:  
1. Conventional total mesorectal excision (TME) surgery (control).  
2. Organ saving treatment using long course concurrent chemoradiation 
(CRT).  
3. Organ saving treatment with short course radiotherapy (SCRT). 
Following initial organ saving treatment (groups 2 and 3), clinical response to 
(chemo)radiotherapy determines the next treatment step. Complete clinical response 
leads to a strategy of watch and wait. A good but incomplete response is followed by 
transanal microsurgery to remove the portion of the bowel wall affected by tumour.  
Little or no response is followed by TME. The primary outcome in phase II is the 
ability increase international recruitment to level that would sustain a larger phase III 
study incorporating pelvic failure as the primary endpoint. This corresponds to four 
cases per month in year 1, rising to 6 per month by the end of year 2. A summary of 
challenges and recommendations can be found in Table 1. 
1. Standardisation of technique 
The Medical Research Council guidance for developing and evaluating complex 
interventions recommends that investigators ‘consistently provide as close to the 
same intervention as possible’ by ‘standardising the content and delivery of the 
intervention’ (14). STAR-TREC compares stable interventions with which surgeons 
will already have reached a standard of expertise (TME or TEMS). However 
significant technical variation can still exist in the provision of these interventions, 
even within a single hospital. Trial design must strike a balance between a pragmatic 
design; a real-word comparative effectiveness study (15), allowing technical and 
non-technical variation in the way in which a surgical intervention and periprocedural 
care is delivered, and an explanatory approach; a design which requires a 
homogenous population, strict standardisation of interventions, and comparison of 
efficacy to a placebo or sham group. Variation can occur not only in the tested 
surgical procedure but also in the timing and delivery of concomitant interventions, 
for example general and regional anaesthesia, chemoradiotherapy, and the provision 
of intensive care support. A complex surgical intervention with multiple components 
can act inter-dependently or independently to influence outcomes (16). In a 
pragmatic randomised trial the fidelity of an intervention must be sufficient to ensure 
the experimental intervention is being uniformly tested, but not so prescriptive that 
translation into real-world practice is not possible. Tools such as PRagmatic 
Explanatory Continuum Indicator Summary (PRECIS-2) have been used to model 
the ‘pragmatism’ of a trial across phases of its design, and judge the extent to which 
effectiveness, rather than efficacy is being tested (17). 
Description of the technique is also important to ensure robust meta-analysis (16). 
30% of surgical trials only report the name of the procedure, without further detail of 
the procedural steps, or standardisation (18). There are three ways to describe a 
surgical intervention: 1. By the overall technical purpose of an operation (e.g. 
removal of the appendix); 2. By its key component parts; 3. By the steps within each 
component part (19). Direct observation, video-monitoring, or semi-structured 
interviews with surgeons performing a procedure can help to define these (20). For 
each step or component, it must be decided which are mandatory, prohibited, or 
optional and the degree of flexibility allowed within this structure. These must be 
described fully in the study protocol including the context of intervention delivery and 
operator expertise according to CONSORT-NPT guidelines (18, 21). Recording of 
essential and prohibited steps is essential to ensure that patient-level meta-analysis 
can be conducted, and interventions can be readily adopted into practice (22, 23). In 
a 2013 review (22), only 34% of non-pharmacological trial interventions had further 
information available online, and much was inaccessible. Monitoring of adherence to 
these will allow assessment of the fidelity of the surgical intervention, and identify 
protocol violation (16). This can be performed using video, or photographic evidence, 
direct observation or self-reporting.  
STAR-TREC has specific Quality Assurance measures embedded into the study 
protocol that will allow monitoring of the delivery a standardised technique for TME, 
TEMS and chemoradiotherapy. These include a pre-trial facility questionnaire, 
process document, and benchmarking cases, and within-trial standardised 
histopathological assessment, individual case review and intraoperative case record 
forms. 
Recommendation: A pragmatic design in surgical trials facilitates the direct 
implementation of effectiveness data into practice. Standardisation of a procedural 
technique with a structured typology ensures high-quality reporting and patient-level 
meta-analysis. 
2. Pilot and feasibility studies 
Feasibility studies are used to test the deliverability of a full, randomised controlled 
trial. This includes the clinician and patient acceptability of interventions, the ability of 
research staff to randomise, outcome selection and assessment, minimal clinically 
important differences, and the robustness of pathways for follow-up. Pilot studies are 
miniature versions of a main trial. As such they typically involve a small cohort of 
patients (commonly around forty (24)), use outcome measures which facilitate the 
delivery of the main trial, but importantly are not powered to test the research 
hypothesis. Internal pilot studies run seamlessly into a main trial, but don’t allow for 
large-scale adaptation of the trial protocol following interim analysis. External pilot 
studies pause for analysis before running into an externally funded phase III trial, so 
facilitate more radical changes to a study protocol (e.g. change of the primary 
outcome measure). Pilot studies may facilitate sample size and power calculations 
for a phase III trial (25), in conjunction with reported event rates from the literature. In 
trials in surgical oncology where complex interventions are tested, feasibility and pilot 
studies allow an assessment of the deliverability of a trial, ahead of a full phase III 
study. 
In STAR-TREC the co-primary outcome measures for the phase III trial will be pelvic 
cancer recurrence, and change in a selected disease-specific quality of life measure 
(e.g. EORTC QLQ CR29 & C30). However, for the feasibility study (which includes 
an external pilot phase), the primary outcome measure is the number of patients 
recruited to the study. This was selected due to unanswered questions regarding the 
delivery and design of the main trial, for example:  
• would patients understand the trial interventions?  
• would clinicians be able to adequately describe equipoise?  
• would intensive follow-up be possible following the organ-sparing treatment? 
Funding bodies are increasingly recognising the importance of feasibility and pilot 
studies in reducing research waste, with specific funding sources readily available. 
Recommendation: Consider a feasibility study, with an internal or external pilot 
phase, where there is uncertainty about the deliverability of a main trial.  
3. Balancing treatments 
Explaining the comparison of two very different treatments to patients can be 
challenging. Surgeons may inherently favour operative management, as they are 
invested in their technique and training, and are more familiar with consenting a 
patient for operative treatment (26). As such, surgeons can struggle to present a 
non-operative strategy in a balanced light, even where community equipoise is 
present (27). The successful recipe for presenting balanced treatments requires 
clinician and/or community equipoise, and a pre-prepared description of 
interventions being tested, supplemented by a well-designed ‘Patient Information 
Sheet’ (PIS)(28).  
Patients often have treatment preferences, and this can impact on the ability to 
recruit and lead to reporting or detection bias(29). Patient preconceptions regarding 
a treatment, or preference towards one arm can be gently tested during the informed 
consent process. It is the clinician’s duty to ensure that the patient does not have 
incomplete knowledge upon which they are based their preference. Restoring 
equipoise can be assisted by exploring false beliefs about one, or both study groups, 
and providing details and figures to restore balance. When balancing treatments, it is 
important to discuss differences in future outcome assessment and follow-up as well 
as the interventions themselves, and the potential impact of this. For instance, in 
STAR-TREC those undergoing organ-sparing therapy required more intensive follow 
up than those undergoing primary TME (clinical examination with flexible endoscopy 
and magnetic resonance imaging every 3 months), which may potentially be 
disruptive to their working and family lives. Leaving time for patients to think about 
the implications of being in a trial is mandated in most trials of elective interventions. 
In trials of emergency care (e.g. emergency laparotomy for a perforated colonic 
cancer), window periods can be shortened or consented deferred until after surgery, 
conditional upon impaired capacity at the time of presentation, and pre-approval by 
local and national ethics committees.  
Recommendation: Prepare balanced explanations for both operative and non-
operative treatments. Restoring patient equipoise is possible if they have incomplete 
information about one of both of the study arms. 
4. The recruitment pathway 
Patients want to be offered the opportunity to be involved in high-quality research. In 
a UK survey of two large cancer centres, 91% of respondents thought patients 
should be involved in research, and half agreed to be randomised to a comparative 
effectiveness study (30). Clear communication and an informed consent pathway 
adherent to standard Good Clinical Practice consent guidelines has been 
demonstrated to increase recruitment rates to trials in cancer therapy (31, 32).  
The recruitment consultation is a core component of the recruitment pathway. Core 
components include: 1. Normalising the research process, 2. Describing clinical 
equipoise, 3. Balancing treatments, 4. Exploring preferences, 5. Communicating the 
purpose and process of randomisation. Terminology regarding allocation and 
randomisation can be particularly troubling for patients, who may feel they are ‘losing 
out’, that you are not taking their condition seriously (‘flip of a coin’, or ‘roll of a dice’). 
Conversely patients may believe that a computer is assigning them a treatment 
based on any one of their or their disease characteristics. Involving patients as 
partners in research has been demonstrated to create a more positive recruitment 
consultation experience(33). Doctors and nurses may also display unease in 
approaching patients for research consent, especially if unfamiliar with eligibility 
criteria, unsure about effectiveness of interventions, or if conflict exists between their 
research and clinical commitments (34). 
It is important to recognise that the recruitment consultation is just one part of the 
informed consent process. In STAR-TREC eligible patients receive a patient 
information sheet at the earliest opportunity. Eligible patients are identified as part of 
multidisciplinary team meetings by the study team, with leadership from cancer 
surgeons in specialist and non-specialist centres playing a crucial role (35-37). The 
recruitment pathway generally incorporated several interviews based around 
outpatients and the endoscopy suit, allowing time for the exchange of information. 
Once a study has opened it is important to monitor screening logs of eligible patients 
and recruitment rates across all centres. Where recruitment in surgical trials is failing 
specific qualitative interventions have been described (33, 38, 39). The most 
commonly reported causes of recruitment failure included unease with 
randomisation, a perceived loss of autonomy, poor understanding of the research, 
and mistrust of the recruiting clinician (40). STAR-TREC has prospectively 
considered monitoring of randomisation, with visits to be triggered by lower than 
expected recruitment from screening logs, poor data quality, or excessive number of 
participant withdrawals or deviations. 
Targeting good recruitment practices can begin early. Evidence-based training 
courses such as Generating Student Recruiters for Randomised Trials (41) train 
delegates (medical students and postgraduate trainees) how to communicate 
equipoise and randomisation as part of an informed consent process. 
Recommendation: Embed recruitment training into your site set-up package. Once 
set-up, identify sites where recruitment rates are low, and provide site-specific 
training using an evidence based course, or intervention. Multidisciplinary team 
meetings can be a great opportunity to identify eligible patients for cancer trials. 
5. Outcome measures 
Choosing the correct primary and secondary outcome measures for trials in surgical 
oncology ensure meaningful, patient-centred trial design (42). The Core Outcome 
Measures in Effectiveness Trials (COMET) initiative has facilitated the development 
and application of a number of ‘core outcome sets’ (COS) for malignant diseases 
through Delphi consensus processes  (43-46). A COS is an agreed minimum set of 
outcomes that should be measured and reported in all clinical trials of a specific 
disease or trial population (47). Quality of life (QOL) measures are now routinely 
included within core outcome sets. A well designed QOL measure should be reliable 
(measures what is intended to measure), valid (measures the correct outcome), and 
responsive (changes in response to changes in a patient’s condition)(48). These can 
be generic health-related QOL measures such as EQ-5D or SF-36, disease-, or 
system-specific. Disease- or system-specific measures tend to have a better 
sensitivity and specificity than generic measures, but do often do not give an overall 
sense of patient wellbeing (49). All tested outcomes should be prospectively included 
within the trial protocol, and reported in accordance with this protocol, without 
deviation (50). 
In organ preservation trials in rectal cancer surgery versus radical surgery to date 
QoL measures are largely missing, or use tools without validation, or with a poor 
magnitude of difference. The STAR-TREC study will collect a panel of disease and 
system specific QoL measures, including EORTC QLQ CR29 & C30, LARS score 
and ICIQ-MLUTS. Use of generic QoL measures such as EuroQol EQ-5D will aid 
assessment of the broader impact of treatment. 
Recommendation: Where possible, include disease-specific, validated quality-of-life 
measures, complemented by a generic QOL measure as co-primary or secondary 
endpoints in trial design, guided by your public and patient representatives. 
6. Patient and public representation 
Patient and public involvement (PPI) in research ensures that we are ‘experimenting 
with’ not ‘experimenting on’ patients (51). Mismatch between clinicians and patients 
in identifying research topics(52) is particularly relevant in colorectal surgery, where 
potential benefits of treatment are counterbalanced by potentially deleterious effects 
on long-term quality of life. In 2015, the UK National Institute of Health Research 
launched a strategic review of Patient and Public Involvement in research, producing 
the document ‘Going the Extra Mile’ (53). This focussed on embedding PPI in the 
culture of research design and conduct, and improving access and strategy for 
effective involvement. PPI has been demonstrated to have a multitude of benefits to 
trials, improving study design, communication with participants, recruitment, 
interpretation and communication of results (54). Patient involvement in responsive 
(e.g. advisory groups) and managerial (e.g. trial management groups) have been 
demonstrated to be more impactful in clinical trials than in oversight roles (e.g. trial 
steering committee)(55).  
For STAR-TREC, the importance and relevance of the organ sparing surgery for 
early rectal cancer was endorsed at a national patient, public and charity 
involvement meeting (56). The trial development and management groups both 
incorporated PPI representatives to ensure the design and delivery of patient 
orientated research. Patient involvement was specifically impactful in choosing 
primary endpoints, determining an acceptable frequency of surveillance, and in 
quality-assuring patient facing information; this often lacks the clarity required for 
informed decision making (57). When planning a trial in surgical oncology, consider 
not only the involvement of PPI representatives in research design and conduct, but 
also the training and continuing development needs they will have to complete the 
role. 
Recommendation: Embed patient and public representation into every stage of your 
research programme to ensure impactful, patient-centred research. 
 
  
Trial Example 2: ROCSS 
Reinforcement of Closure of Stoma Site. A randomised controlled trial of 
reinforcement of closure of stoma site using a biological mesh (ISRCTN46330337). 
Trial Summary 
ROCSS is a phase III randomised controlled trial to assess the effectiveness of 
placing a biological mesh at the site of stoma closure to prevent incisional herniation. 
Participants are randomised in a 1:1 ratio to:  
1. Stoma site closure with a pre-peritoneal collagen mesh (Strattice®) 
2. Standard stoma site closure with surgeon’s choice of suture material.  
The primary outcome measure is the rate of clinical herniation at 2 years 
postoperatively. A summary of challenges and recommendations can be found in 
table 1. 
7. Trainee-led networks 
The ROCCS study was designed and delivered by the West Midlands Research 
Collaborative. Surgical research collaboratives are groups of doctors in surgical 
training that work together to deliver patient-level, multi-centre, protocol-driven 
research and audit projects. This approach allows for large numbers of patients to be 
included in short time periods, and permits greater generalisability than single-centre 
studies. Surgical research collaboratives exist across the UK (58), Europe (59-62) 
and are emerging in low-middle income environments (63-68). These trainee groups 
have played a key role in the delivery of several high-quality randomised trials to 
date (69-71).  
The ROCSS study demonstrated the benefits of trainee-led research groups in the 
delivery of multicentre trials. Firstly, with the appropriate mentorship a research-
active cohort of future trial leaders and recruiters emerged, each equipped with Good 
Clinical Practice training. Secondly, trainees are well represented at various points 
along the patient pathway (outpatient clinics, assessment units, emergency 
departments, inpatient wards, and operating theatres) and are therefore uniquely 
positioned to recruit and randomise eligible patients that may have been difficult to 
identify within traditional research models. Thirdly, the rotational nature of the UK 
surgical training system (spending six to twelve months in a single hospital before 
transferring to another) facilitated the dissemination of the trial around regional and 
national centres, and crosses political boundaries.  
Recommendation: Collaboration with trainee-led networks supports the delivery of 
multicentre trials in surgical oncology and develops future research leaders. 
8. Randomisation 
The purpose of randomisation is to create broadly matched groups who have similar 
known and unknown factors that could influence study outcome. However, selection 
bias can still occur with dropout or crossover due to failure of allocation concealment, 
or pseudo-randomisation: use of predictable quasi-randomisation, such as allocation 
by date of birth, sealed envelopes, or medical record number. As such randomisation 
should occur close to the time of intervention to mask the patient’s allocation (72). 
In the ROCCS trial randomisation was performed by an investigator in the 
anaesthetic room at the point of induction. An independently administered online and 
24-hour telephone randomisation service ensured randomisation concealment, and 
minimised risk of selection bias. A minimisation procedure was used to ensure 
balance for clinically plausible factors effecting the primary endpoint; operative 
contamination, creation of a new stoma, or an emergency operation.  
Recommendation: Multimodal access to randomisations services (e.g. telephone 
and online), with minimum time from randomisation to the intervention optimises 
allocation concealment and minimises risk of selection bias. 
9. Novel techniques and training 
Scientific evaluation of novel surgical interventions is complicated. Innovations can 
undergo iterative modifications, hold ambiguity in definition, lack consensus for 
outcome evaluation, vary significantly in response to operator capabilities, and be 
subject to strong treatment preferences. As a consequence, only 10.3% of 
implantable intraabdominal devices (such as biological mesh) are supported by 
evidence from a published RCT with low risk of bias (73). 
The IDEAL (Idea-Development-Exploration-Assessment-Long term) collaboration 
(10, 13, 74) have described a five-stage, stepwise framework for the development 
and evaluation of surgical innovation. The ‘Idea’ stage: 1 deals with proof of concept 
and first-in-man studies. The ‘Development’ stage: 2a refines technical details as 
experience progresses, and the ‘Exploration’ stage: 2b defines a standardised, 
stable procedure, with the obstacles to a definitive trial addressed. The ‘Assessment’ 
stage: 3 explores effectiveness of the standardised innovation versus standard care 
in randomised clinical trial. ‘Long-term’ evaluation: 4 maintains surveillance of the 
innovation using prospective databases and registries to identify rare and late 
outcomes, and broadened the applicability of the technique to novel patient groups. 
The ROCSS study, described a novel technique for the placement of intraperitoneal 
biological mesh to prophylactically reinforce stoma closure sites (75). The feasibility 
and internal pilot studies followed IDEAL recommendations for the development of 
innovation (phase 1 to 2b) before the full IDEAL phase 3 trial testing the ‘stable’ 
technique. A technical paper was produced from IDEAL 1 (Idea) and 2a 
(Development) phases (75). This described in detail the procedure and 
periprocedural care, from proof of concept to the first seven cases in humans, 
providing follow-up data on safety, technical and procedural success. Appropriate 
ethical approvals were sought.  The IDEAL phase 2b study was described as part of 
an internal pilot trial (76) of 90 patients in eight hospitals. This feasibility study 
reported the ability to recruit to a phase 3 study (90 patients within 12 months), the 
ability to randomise (greater than 50% eligible patients randomised), and 
deliverability and safety of the novel mesh placement technique. This demonstrated 
community learning and maturation of the procedural steps. Early publication of 
blinded, short-term safety data minimised the risk of harm to future patients 
undergoing the novel procedure ahead full comparative effectiveness data being 
made available. 
Dissemination of the ROCSS technique was a key consideration in delivery of a 
IDEAL phase 3 trial. The standardised technique was presented in full in a training 
video (77) and an instructional, illustrated technical guide was produced (75). Live 
training cases were recorded and made available to operators to facilitate rapid 
uptake. The trial management group performed one-to-one mentoring of local 
Principle Investigators (PI) during joint cases at site set-up visits, allowing real-time 
training with an expert operator. PIs then disseminated the technique further within 
their centres. After site visits, open workshops were made available for participating 
surgeons to review the technique and local PIs were offered the opportunity to attend 
theatre within the trial Chief Investigators centre at their convenience. Self-reported 
adherence to the standardised technique allowed procedure-to-procedure monitoring 
and response to any procedural adaptations. 
Recommendation: Follow IDEAL recommendations for evaluation of surgical 
innovations. Carefully consider your investigator training strategy to ensure 
consistent application of the standardised technique.  
10. Learning curves 
Variation in outcome following surgery can occur as a direct result of the skill-set of 
the operator. For novel techniques, a procedure-specific ‘learning curve’ effect can 
be seen up to the point of ‘expertise’. Interventions in IDEAL phase 3 trials should be 
‘stable’ with operators performing this optimally before comparisons are made (i.e. 
proficient in both the control (stoma closure) and intervention (mesh closure) 
procedure). However, changes in performance over time can happen even for fully 
trained surgeons (78, 79). This means that technical performance can improve even 
in the ‘standard care’ arm of a trial involving a novel therapy, risking contamination of 
the control arm and masking of a positive effect (80). 
Learning curves have been addressed by stipulating a minimum number of 
procedures performed for eligibility (78, 81), or by statistical adjustment for the 
learning curve effect by controlling for expertise and experience in the analysis of 
outcome measures (e.g. using Bayesian hierarchical models (78, 82)). Another 
solution has been proposed as ‘expertise-based designs’, where different expert 
operators in each centre perform each procedure, requiring stratification of 
randomisation by surgeon and by centre (83). The most common proxy for judging 
the ‘expertise’ of surgeons in oncology trials is time (84), represented as the total 
number of cases performed inside and outside of the study period (accessible via 
surgeons’ logbooks). Other proxies have included the number of cases performed 
annually in the centre (accessible via national hospital-level statistics and national 
registries), the level of training of the operating surgeon (according to local, or 
national hierarchies of training), specific intra- or post-operative outcomes or via 
workplace based competency assessments (84, 85). Qualitative research may also 
assist the definition of procedure-specific technical proficiency (86). 
In the ROCSS trial, the protocol mandated that the operating surgeon should have 
performed a minimum of 20 previous stoma closures, in line with consensus process 
amongst the Trial Steering Group. A priori learning effect analyses will determine any 
case-volume relationships in subsequent analyses. 
Recommendation: Case report forms should clearly record prior experience of 
participating surgeons. Pre-defined learning curve analyses improve generalisability 
of study findings and lead to more accurate treatment effect estimates by adjusting 
for a large source of variability. 
11. Blinding 
Blinding (concealment of a patients group allocation after randomisation) can be 
difficult in surgical trials and introduce performance or detection bias (87). Typically 
blinding is considered in three dimensions; blinding of the patient, blinding of the 
operator, blinding of the outcome assessor (88). In surgical trials, blinding of the 
surgeon and the patient can be difficult. For example, tested groups may have 
different scars, or go through different treatment pathways. This can lead to 
differences in patient behaviour, responses to treatment and reporting of adverse 
events. More subjective measures such as quality of life measures are most subject 
to measurement bias when compared to definite endpoints (e.g. mortality). In the 
ROCSS trial as the stoma site closure was performed through the same incision, it 
was possible to blind the patient, but not the surgeon to the group allocation. 
Creative techniques for trials where incisions or repairs are visibly different between 
group such as standardisation of wound dressings have been employed with some 
success (89). Placebo controlled surgical trials with ‘sham surgery’ have also been 
performed (90), however there is a number of ethical concerns in the setting of 
surgical oncology. Outcome assessment is the easiest stage to blind within surgical 
trials. In the ROCSS trial blinded review of cross-sectional imaging for evidence of 
hernia recurrence was performed by consultant radiologists. 
Recommendation: Blinding of outcome assessors is an easy way of maximising 
internal validity in surgical trials. Innovative methods for achieving blinding in surgical 
trials have been demonstrated. 
12. Follow-up 
Loss to follow-up presents a major risk to internal validity as it leaves a specific 
population where the primary outcomes remains unassessed (for example those that 
have died, suffered significant morbidity, or moved abroad). Attrition bias occurs 
where different groups are lost to follow-up in different treatment arms. The ROCCS 
trial was susceptible to patient loss at follow-up, as assessment of the primary 
outcome, clinical stoma site herniation, was recorded 2 years postoperatively. 
In order to improve concordance with follow-up in ROCSS, patients who missed their 
initial follow-up appointment at 2 years were offered a small financial incentive 
(£20GBP gift voucher) in exchange for attendance. This dramatically improved 
adherence to follow up, and reduced research waste (i.e. missed appointments, 
clinical and administrative burden). It has been previously demonstrated that 
selective monetary incentivisation can improve adherence to follow-up in 
interventional studies in a cost-effective manner (91). Other strategies described 
include recorded delivery of postal questionnaires, personalised approaches, non-
monetary incentives, prize-draws, behavioural motivators, additional reminders, 
however evidence for the benefit of these is unclear upon meta-analysis  (92). Within 
our experience, patient centred approaches to follow-up such as combining outcome 
assessment with routine appointments may also improve concordance. Any patients 
lost to follow-up despite these efforts were included within the trial CONSORT 
diagram, with specific explanations given for each (93). 
Recommendation: Consider including strategies for maximising concordance with 
primary outcome assessment (e.g. selective monetary incentivisation) within your 
funding application. 
  
Conclusion 
Whilst pragmatic randomised controlled trials offer the ability to compare high quality 
clinical effectiveness data between well-matched groups, trials in surgical oncology 
face significant methodological challenges and should be designed and interpreted 
with caution in light of these. The quality and volume of surgical trials have been 
improved significantly by targeted methodological research over the past two 
decades. Better understanding of the challenges facing trials comparing operative 
versus non-operative management, and novel surgical techniques in the treatment of 
cancer will accelerate high quality evaluation, and maximise benefit for the greatest 
number of patients. 
  
Table 1. Recommendations for randomised trials in surgical oncology 
 Challenge Recommendation 
1 Standardisation of technique 
A pragmatic design in surgical trials facilitates the direct 
implementation of effectiveness data into practice. Standardisation of 
a procedural technique with a structured typology ensures high-quality 
reporting and patient-level meta-analysis. 
2 Pilot and feasibility studies 
Consider a feasibility study, with an internal or external pilot phase, 
where there is uncertainty about the deliverability of a main trial. 
3 Balancing treatments 
Prepare balanced explanations for both operative and non-operative 
treatments. Restoring patient equipoise is possible if they have 
incomplete information about one of both of the study arms. 
4 The recruitment pathway 
Embed recruitment training into your site set-up package. Once set-
up, identify sites where recruitment rates are low, and provide site-
specific training using an evidence based course, or intervention. 
Multidisciplinary team meetings can be a great opportunity to identify 
eligible patients for cancer trials. 
5 Outcome measures 
Where possible, include disease-specific, validated quality-of-life 
measures, complemented by a generic QOL measure as co-primary 
or secondary endpoints in trial design, guided by your public and 
patient representatives. 
6 Patient and public representation 
Embed patient and public representation into every stage of your 
research programme to ensure impactful, patient-centred research. 
7 Trainee-led networks 
Collaboration with trainee-led networks supports the delivery of 
multicentre trials in surgical oncology and develops future research 
leaders. 
8 Randomisation 
Multimodal access to randomisations services (e.g. telephone and 
online), with minimum time from randomisation to the intervention 
optimises allocation concealment and minimises risk of selection bias. 
9 Novel techniques and training 
Follow IDEAL recommendations for evaluation of surgical innovations. 
Carefully consider your investigator training strategy to ensure 
consistent application of the standardised technique. 
10 Learning curves 
Case report forms should clearly record prior experience of 
participating surgeons. Pre-defined learning curve analyses improve 
generalisability of study findings. 
11 Blinding  
Blinding of outcome assessors is an easy way of maximising internal 
validity in surgical trials. Innovative methods for achieving blinding in 
surgical trials have been demonstrated. 
12 Follow-up 
Consider including strategies for maximising concordance with primary 
outcome assessment (e.g. selective monetary incentivisation) within 
your funding application. 
 
  
Figure 1. STAR-TREC Trial Schemata 
 
  
Figure 2. ROCSS Trial Schemata  
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